Abstract
Current ovarian cancer screening guidelines in high-risk women vary according to different organizations. Risk reducing surgery remains the gold standard for definitive treatment in BRCA mutation carriers, but research advancements have created more short-term options for patients to consider. The decisions involved in how a woman manages her BRCA mutation status can cause a great deal of stress and worry due to the imperfect therapy options. The goal of this review was to critically analyze the screening recommendations and alternative options for high-risk ovarian cancer patients and evaluate how these discrepancies and choices affect a woman’s management decisions.
Original language | English (US) |
---|---|
Article number | 57 |
Journal | Cancers |
Volume | 10 |
Issue number | 2 |
DOIs | |
State | Published - Feb 21 2018 |
Externally published | Yes |
Keywords
- BRCA
- CA-125
- Ovarian cancer
- Risk-reducing surgery
- Screening guidelines
ASJC Scopus subject areas
- Oncology
- Cancer Research